Bengaluru’s fast‑medicine startup Plazza announced on 20 July 2026 that it has closed a $15 million Series A round, a move that will accelerate its push into a high‑speed, AI‑driven pharmacy model.

The funding was co‑led by Accel, Elevation Capital and Nexus Venture Partners, with participation from existing backers All In Capital and Better Capital. According to a report in The Mint, the capital will be used to grow Plazza’s physical store footprint. Founder and chief executive Aman Priyadarshi said the company has tested a handful of stores in Bengaluru and plans to open about ten new locations in the next eight weeks. By the end of 2026, Plazza aims to operate roughly 20 stores in the city and to expand to other cities within a year, targeting more than 3,000 stores over the next three to four years.

Plazza was founded in 2024 by Priyadarshi, a former Zomato executive, and Aniruddha Sen. The company’s model focuses on stocking a larger inventory and delivering medicines within 15–30 minutes. Traditional pharmacies typically carry 5,000–6,000 items and serve a small catchment area, while established online pharmacies prioritize inventory breadth over speed. Plazza’s stores carry over 40,000 SKUs, according to the company, and use artificial intelligence to build store‑specific inventories that reflect micro‑market demand.

The startup’s AI‑driven inventory system adapts each store’s assortment to neighbourhood‑level prescribing patterns. In its two Bengaluru stores, only about 50 % of the top‑selling medicines overlap, illustrating how prescription behaviour varies across micro‑markets. Plazza said the fresh capital will also strengthen its technology platform, deepening AI‑driven inventory and assortment intelligence.

Plazza’s growth has been rapid. The company reported a 27‑fold increase in gross merchandise value (GMV) between June 2025 and March 2026. The Indian organised pharmacy market is highly consolidated, dominated by giants such as Tata 1mg and Apollo 24/7. Funding activity in the space has been limited, with most capital directed toward firms addressing specific gaps. For example, generics‑focused Truemeds raised $85 million in a Series C round in August 2025, led by Accel and Peak XV, while PlatinumRx raised $6 million in a Series A round in September 2025, led by Stellaris Venture Partners.

Plazza’s focus on speed and AI‑enabled inventory differentiates it from competitors that prioritise inventory breadth. The company’s omnichannel model places a large portion of its space in inventory storage, enabling efficient manpower planning and store design. Priyadarshi said the company expects customers to place orders via its app or WhatsApp, after which the delivery is executed.

The funding round comes at a time when investors are increasingly interested in niche health‑tech categories. Accel, a long‑time investor in consumer and enterprise tech, has also backed other Indian health‑tech firms, including Truemeds. Elevation Capital and Nexus Venture Partners have a history of investing in early‑stage startups with high growth potential.

In summary, Plazza’s $15 million Series A provides the capital needed to scale its store network, enhance its AI‑driven inventory platform, and accelerate its rapid‑delivery promise. The company’s next milestones include opening 20 stores in Bengaluru by year‑end, expanding to additional cities, and further deepening its technology stack to support a projected 3,000‑store network.